Entity

Time filter

Source Type

Emeryville, CA, United States

Debabov D.,NovaBay Pharmaceuticals
Applied Biochemistry and Microbiology | Year: 2013

Microbial resistance is emerging faster than we are replacing our armamentarium of antimicrobial agents. Resistance to penicillin developed soon after it was introduced into clinical practice in 1940s. Now resistance developed to every major class of antibiotics. In healthcare facilities around the world, bacterial pathogens that express multiple resistance mechanisms are becoming common. The origins of antibiotic resistance genes can be traced to the environmental microbiota. Mechanisms of antibiotic resistance include alterations in bacterial cell wall structure, growth in biofilms, efflux pump expression, modification of an antibiotic target or acquisition of a new target and enzymatic modification of the antibiotic itself. Specific examples of each mechanism are discussed in this review. Some approaches to counter resistance include antibiotic stewardship, co-administration with resistance inhibitors, exploiting genome data in search of new targets and use of non-antibiotic antimicrobials for topical indications. A coordinated effort from government, public and industry is needed to deal with antibiotic resistance health care crisis. © 2013 Pleiades Publishing, Inc. Source


Gottardi W.,Innsbruck Medical University | Debabov D.,NovaBay Pharmaceuticals | Nagl M.,Innsbruck Medical University
Antimicrobial Agents and Chemotherapy | Year: 2013

Antibiotic resistance is a growing public health crisis. To address the development of bacterial resistance, the use of antibiotics has to be minimized for nonsystemic applications in humans, as well as in animals and plants. Possible substitutes with low potential for developing resistance are active chlorine compounds that have been in clinical use for over 180 years. These agents are characterized by pronounced differences in their chlorinating and/or oxidizing activity, with hypochlorous acid (HOCl) as the strongest and organic chloramines as the weakest members. Bacterial killing in clinical practice is often associated with unwanted side effects such as chlorine consumption, tissue irritation, and pain, increasing proportionally with the chlorinating/oxidizing potency. Since the chloramines are able to effectively kill pathogens (bacteria, fungi, viruses, protozoa), their application as anti-infectives is advisable, all the more so as they exhibit additional beneficial properties such as destruction of toxins, degradation of biofilms, and anticoagulative and anti-inflammatory activities. Within the ample field of chloramines, the stableN-chloro derivatives of ß-aminosulfonic acids are most therapeutically advanced. Being available as sodium salts, they distinguish themselves by good solubility and absence of smell. Important representatives areN-chlorotaurine, a natural compound occurring in the human immune system, and novel mono- and dichloro derivatives of dimethyltaurine, which feature improved stability. Copyright © 2013, American Society for Microbiology. Source


Patent
NovaBay Pharmaceuticals | Date: 2014-10-31

The present invention relates generally to systems and methods for cleaning and disinfecting contact lenses. In various respects, the invention is directed to an insulated system that reduces heat loss from catalyzed neutralization of a disinfecting solution resulting in an increased temperature of the disinfection solution during the disinfection process and neutralization of the disinfection solution. The increased temperature increases the kill rate (i.e., better reduction) of microorganisms present on the lenses, and increases the neutralization rate of the disinfection solution. Increase of the kill rate allows better reduction of microorganisms resistant to elimination using previous systems and methods, (e.g.,


Patent
NovaBay Pharmaceuticals | Date: 2012-11-14

This application describes compounds useful as anti-microbial agents, including as antibacterial, disinfectant, antifungal, germicidal or antiviral agents.


DELRAY BEACH, Fla.--(BUSINESS WIRE)--Delray Eye Associates announced today that Delray ophthalmologist Steven I Rosenfeld, MD, FACS, who specializes in medical and surgical treatments of corneal conditions, infectious and inflammatory eye diseases, has written an article in Ophthalmic Professional describing how a new eyelid and lash hygiene product called Avenova™ successfully managed the eyelid disease of a particularly challenging patient. As Dr. Rosenfeld describes, the 68-year-old man had suffered from constant and chronic symptoms of dry eyes, redness, tearing, intermittent foreign body sensation, and sharp shooting pains for more than two years. The patient had tried eye drops, ointments, baby shampoo, tea tree oil and a variety of eye scrubs. He had even seen eight other ophthalmologists before coming into Dr. Rosenfeld’s office. Despite all that, “…the patient said he failed to gain relief,” Dr. Rosenfeld writes. In fact, previous treatments had made his vision blurry and made him feel even worse. Dr. Rosenfeld’s examination showed the man had chronic blepharitis, a condition typically caused by bacteria growing on the eyelids, resulting in redness, inflammation, pain and a crusty build-up. The man’s meibomian glands were also plugged, preventing the oily substance produced by the glands from reaching the tear film on the eye. That oily substance is crucial, since it prevents the tears from evaporating and making the eye dry. Moreover, his eyelashes were also turned inward, a condition called trichiasis, along with other conditions. Dr. Rosenfeld prescribed the use of Avenova once a day. The product is very easy to use. Patients spray it onto a cotton pad and wipe their eyelids and lashes. It worked. Within two weeks of daily use “…the patient felt much better and progressed with each subsequent visit,” Dr. Rosenfeld reports. And when last examined, two months after the treatment started, “…he was very pleased with the comfort of the lid scrub system, and the treatment effectively controlled the symptoms of the patient’s lid margin disease…. Avenova has helped me to make this patient comfortable,” Dr. Rosenfeld writes. In the article, Dr. Rosenfeld also describes the science behind Avenova. It contains what manufacturer NovaBay Pharmaceuticals (NYSE MKT:NBY) calls Neutrox™, the company’s proprietary, pure hypochlorous acid (HOCl). Lab tests show that, in solution, it rapidly eradicates 20 species of pathogens, including antibiotic-resistant Staphylococcus aureus. “This rapid killing of microorganisms helps prevent harmful biofilms from forming,” Dr. Rosenfeld explains. “In addition, Neutrox in vitro inactivates bacterial toxins that can cause inflammation.” Plus, it is completely safe and refreshing to use, patients report. Dr. Rosenfeld concludes that Avenova should be used for the management of many eyelid diseases and conditions, not just for challenging patients like the one described in the article. “I would recommend Avenova for any lid hygiene regimen, including dry eye, blepharitis, ocular surgery and contact lens wear,” concludes Dr. Rosenfeld.

Discover hidden collaborations